BIORCHESTRA is a biotherapeutics company focused on degenerative and rare Central Nervous System (CNS) diseases, leveraging a proprietary Brain Targeting RNAi Nanomedicine platform combining targeted cell and tissue delivery with proprietary RNA interference chemistries to develop first and best-in-category RNA therapeutics.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
MA
Company HQ Country:
United States
Year Founded:
2018
Main Therapeutic Focus:
CNS/Neurological
Lead Product in Development:
BMD-001 targeting Alzheimer's ALS and Parkinson's disease
Development Phase of Primary Product:
Pre-Clinical
Number Of Unlicensed Products (For Which You Are Seeking Partners):
6
Speaker
